Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, under the ticker symbol WWB, marking a significant milestone for the Shanghai-rooted immunology firm.
The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock sharply higher on the first day of trading. Shares closed at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong opening performance by any measure in the current biotech capital markets environment.
Read more M&T Bank Raises Quarterly Dividend 20% to $1.80 Per Share →
Windward Bio operates in the immunology space, a therapeutic area that has drawn sustained investor interest given the potential of novel biologics and targeted therapies to address autoimmune and inflammatory conditions. The company's listing adds to a roster of China-linked biotechs that have pursued US public market access through Nasdaq in recent years.
Qiming Venture Partners, one of Asia's prominent venture capital firms with a track record of backing life sciences companies, holds a portfolio stake in Windward Bio. The firm's involvement signals institutional confidence in the biotech's clinical pipeline ahead of further development milestones.
Continue reading at All Financial Services & Investing.